Logo image of AMLX

AMYLYX PHARMACEUTICALS INC (AMLX) Stock Fundamental Analysis

USA - NASDAQ:AMLX - US03237H1014 - Common Stock

14.17 USD
-0.14 (-0.98%)
Last: 10/24/2025, 8:08:53 PM
14.17 USD
0 (0%)
After Hours: 10/24/2025, 8:08:53 PM
Fundamental Rating

3

AMLX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. AMLX has a great financial health rating, but its profitability evaluates not so good. AMLX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AMLX has reported negative net income.
AMLX had a negative operating cash flow in the past year.
In the past 5 years AMLX reported 4 times negative net income.
In the past 5 years AMLX reported 4 times negative operating cash flow.
AMLX Yearly Net Income VS EBIT VS OCF VS FCFAMLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -96.40%, AMLX is doing worse than 75.92% of the companies in the same industry.
The Return On Equity of AMLX (-111.75%) is worse than 63.35% of its industry peers.
Industry RankSector Rank
ROA -96.4%
ROE -111.75%
ROIC N/A
ROA(3y)-65.66%
ROA(5y)-116%
ROE(3y)-76.67%
ROE(5y)-224.39%
ROIC(3y)N/A
ROIC(5y)N/A
AMLX Yearly ROA, ROE, ROICAMLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AMLX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMLX Yearly Profit, Operating, Gross MarginsAMLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

AMLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AMLX has been increased compared to 1 year ago.
The number of shares outstanding for AMLX has been increased compared to 5 years ago.
There is no outstanding debt for AMLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AMLX Yearly Shares OutstandingAMLX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
AMLX Yearly Total Debt VS Total AssetsAMLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 27.65 indicates that AMLX is not in any danger for bankruptcy at the moment.
AMLX's Altman-Z score of 27.65 is amongst the best of the industry. AMLX outperforms 94.76% of its industry peers.
There is no outstanding debt for AMLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 27.65
ROIC/WACCN/A
WACC8.73%
AMLX Yearly LT Debt VS Equity VS FCFAMLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

AMLX has a Current Ratio of 8.72. This indicates that AMLX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.72, AMLX is in the better half of the industry, outperforming 78.53% of the companies in the same industry.
A Quick Ratio of 8.72 indicates that AMLX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 8.72, AMLX is doing good in the industry, outperforming 79.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.72
Quick Ratio 8.72
AMLX Yearly Current Assets VS Current LiabilitesAMLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

AMLX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -420.83%.
AMLX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.86%.
Measured over the past years, AMLX shows a very strong growth in Revenue. The Revenue has been growing by 127.75% on average per year.
EPS 1Y (TTM)-420.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.99%
Revenue 1Y (TTM)-99.86%
Revenue growth 3Y574.28%
Revenue growth 5Y127.75%
Sales Q2Q%100%

3.2 Future

AMLX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.58% yearly.
The Revenue is expected to grow by 20.37% on average over the next years. This is a very strong growth
EPS Next Y26.56%
EPS Next 2Y17.22%
EPS Next 3Y11.2%
EPS Next 5Y14.58%
Revenue Next Year-100%
Revenue Next 2Y-96.76%
Revenue Next 3Y-24.92%
Revenue Next 5Y20.37%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AMLX Yearly Revenue VS EstimatesAMLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
AMLX Yearly EPS VS EstimatesAMLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AMLX. In the last year negative earnings were reported.
Also next year AMLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMLX Price Earnings VS Forward Price EarningsAMLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMLX Per share dataAMLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.22%
EPS Next 3Y11.2%

More info and screens

0

5. Dividend

5.1 Amount

AMLX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMYLYX PHARMACEUTICALS INC

NASDAQ:AMLX (10/24/2025, 8:08:53 PM)

After market: 14.17 0 (0%)

14.17

-0.14 (-0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners71.5%
Inst Owner Change-0.01%
Ins Owners7.77%
Ins Owner Change-0.56%
Market Cap1.51B
Revenue(TTM)416.00K
Net Income(TTM)-187600000
Analysts86.25
Price Target15.17 (7.06%)
Short Float %9.75%
Short Ratio5.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6%
Min EPS beat(2)-1.31%
Max EPS beat(2)13.31%
EPS beat(4)1
Avg EPS beat(4)-9.86%
Min EPS beat(4)-47.75%
Max EPS beat(4)13.31%
EPS beat(8)2
Avg EPS beat(8)-250.07%
EPS beat(12)6
Avg EPS beat(12)-138.26%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)17.82%
PT rev (3m)27.96%
EPS NQ rev (1m)2.5%
EPS NQ rev (3m)1.15%
EPS NY rev (1m)3.7%
EPS NY rev (3m)3.01%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3633.11
P/FCF N/A
P/OCF N/A
P/B 9
P/tB 9
EV/EBITDA N/A
EPS(TTM)-2.5
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)-1.89
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0
BVpS1.57
TBVpS1.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -96.4%
ROE -111.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.66%
ROA(5y)-116%
ROE(3y)-76.67%
ROE(5y)-224.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5343.95%
Cap/Sales 8709.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.72
Quick Ratio 8.72
Altman-Z 27.65
F-Score3
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)1551.62%
Cap/Depr(5y)4086.74%
Cap/Sales(3y)17.77%
Cap/Sales(5y)40.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-420.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.99%
EPS Next Y26.56%
EPS Next 2Y17.22%
EPS Next 3Y11.2%
EPS Next 5Y14.58%
Revenue 1Y (TTM)-99.86%
Revenue growth 3Y574.28%
Revenue growth 5Y127.75%
Sales Q2Q%100%
Revenue Next Year-100%
Revenue Next 2Y-96.76%
Revenue Next 3Y-24.92%
Revenue Next 5Y20.37%
EBIT growth 1Y-157.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.05%
EBIT Next 3Y14.57%
EBIT Next 5YN/A
FCF growth 1Y-122.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.63%
OCF growth 3YN/A
OCF growth 5YN/A

AMYLYX PHARMACEUTICALS INC / AMLX FAQ

What is the fundamental rating for AMLX stock?

ChartMill assigns a fundamental rating of 3 / 10 to AMLX.


Can you provide the valuation status for AMYLYX PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to AMYLYX PHARMACEUTICALS INC (AMLX). This can be considered as Overvalued.


Can you provide the profitability details for AMYLYX PHARMACEUTICALS INC?

AMYLYX PHARMACEUTICALS INC (AMLX) has a profitability rating of 0 / 10.